生命科学资讯

BioMarin to pay $4.8B for Amicus and its rare disease drugs

Senators point fingers over who blocked the rare disease voucher reauthorization

Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail

Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration

Catalent handed two Form 483s, including for Sarepta gene therapy site

Endpoints at JPM 2026: What we'll be talking about

US commission urges action as China's biotech sector advances

UK committee demands ‘much-needed clarity’ on UK-US pharma trade deal

Daiichi and Merck's I-Dxd lung cancer study faces partial hold due to deaths

Endpoints biopharma sentiment survey for Q1 2026

AI startup Edison raises $70M seed for research software

After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset

Biopharma's winners and losers of 2025

Takeda's $4B immunology drug achieves first Phase 3 successes

Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappoints

Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A

Atavistik raises $120M for bleeding disorder, blood cancer drugs

Insilico advances Hong Kong IPO, eyes $260M raise with Lilly's support

Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting

Steve Paul's post-Karuna act draws $165M to schizophrenia biotech Syremis